BioCryst Pharmaceuticals’ (BCRX) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report sent to investors on Wednesday, AnalystRatings.com reports.

Several other equities analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, August 8th. ValuEngine downgraded shares of BioCryst Pharmaceuticals from a buy rating to a hold rating in a report on Monday, November 4th. BidaskClub downgraded shares of BioCryst Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, October 4th. Finally, HC Wainwright reaffirmed a buy rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. BioCryst Pharmaceuticals currently has an average rating of Hold and an average price target of $9.64.

BCRX stock opened at $2.03 on Wednesday. BioCryst Pharmaceuticals has a 1-year low of $1.95 and a 1-year high of $9.95. The firm has a market cap of $224.19 million, a price-to-earnings ratio of -2.07 and a beta of 1.86. The company has a debt-to-equity ratio of 2.38, a current ratio of 1.44 and a quick ratio of 1.43. The firm has a fifty day moving average price of $2.53 and a two-hundred day moving average price of $3.71.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.03). BioCryst Pharmaceuticals had a negative net margin of 1,091.44% and a negative return on equity of 371.33%. The firm had revenue of $1.78 million for the quarter, compared to analyst estimates of $4.54 million. As a group, analysts expect that BioCryst Pharmaceuticals will post -1.23 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of BCRX. BlackRock Inc. lifted its holdings in BioCryst Pharmaceuticals by 2.6% in the 2nd quarter. BlackRock Inc. now owns 8,925,891 shares of the biotechnology company’s stock valued at $33,831,000 after acquiring an additional 228,525 shares during the last quarter. Vanguard Group Inc. lifted its holdings in BioCryst Pharmaceuticals by 10.7% in the 2nd quarter. Vanguard Group Inc. now owns 6,692,444 shares of the biotechnology company’s stock valued at $25,365,000 after acquiring an additional 648,937 shares during the last quarter. FMR LLC lifted its holdings in BioCryst Pharmaceuticals by 15.9% in the 1st quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock valued at $28,229,000 after acquiring an additional 475,989 shares during the last quarter. UBS Group AG lifted its holdings in BioCryst Pharmaceuticals by 331.0% in the 2nd quarter. UBS Group AG now owns 2,202,794 shares of the biotechnology company’s stock valued at $8,349,000 after acquiring an additional 1,691,681 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its holdings in BioCryst Pharmaceuticals by 11.4% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 1,491,354 shares of the biotechnology company’s stock valued at $5,652,000 after acquiring an additional 152,659 shares during the last quarter. 90.67% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Recommended Story: How to interpret a stock’s beta number

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.